4.6 Article

Graft-versus-host disease Part II. Management of cutaneous graft-versus-host disease

Journal

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
Volume 66, Issue 4, Pages 535-552

Publisher

MOSBY-ELSEVIER
DOI: 10.1016/j.jaad.2011.11.961

Keywords

cyclosporine; extracorporeal photopheresis; graft-versus-host disease; hematopoietic cell transplantation; imatinib mesylate; mycophenolate mofetil; phototherapy; tacrolimus; rituximab

Categories

Funding

  1. National Cancer Institute, Center for Cancer Research

Ask authors/readers for more resources

Dermatologists are ideally suited to manage the various cutaneous sequelae of graft-versus-host disease (GVHD) outlined in part I of this review. However, the complexity of the patient with GVHD, including comorbidities, potential drug interactions related to polypharmacy, and the lack of evidence-based treatment guidelines, are significant challenges to optimizing patient care. In this section, we will provide an outline for the role of the dermatologist in a multispecialty approach to caring for patients with GVHD. (J Am Acad Dermatol 2012;66:535.e1-16.)

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available